Lisata Therapeutics, Inc. (NASDAQ:LSTA) Stock Short Interest Drops 76.1%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 39,407 shares, a decrease of 76.1% from the September 15th total of 164,953 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 362,256 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.

Lisata Therapeutics Trading Down 0.9%

NASDAQ LSTA traded down $0.01 during trading hours on Monday, hitting $1.05. 160,669 shares of the company’s stock traded hands, compared to its average volume of 193,065. Lisata Therapeutics has a 52 week low of $0.98 and a 52 week high of $5.07. The firm has a market capitalization of $9.46 million, a P/E ratio of -0.64 and a beta of 0.94. The business’s fifty day moving average price is $1.43 and its two-hundred day moving average price is $2.72.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.32) earnings per share for the quarter. On average, sell-side analysts expect that Lisata Therapeutics will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Lisata Therapeutics during the second quarter valued at about $1,730,000. Bank of America Corp DE purchased a new stake in Lisata Therapeutics in the second quarter worth about $35,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Lisata Therapeutics in the second quarter worth about $157,000. GSA Capital Partners LLP bought a new position in shares of Lisata Therapeutics in the second quarter worth about $321,000. Finally, Renaissance Technologies LLC raised its stake in shares of Lisata Therapeutics by 6.5% in the first quarter. Renaissance Technologies LLC now owns 131,715 shares of the company’s stock worth $660,000 after buying an additional 8,000 shares during the period. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies intended to improve the treatment of solid tumors. The company’s approach centers on tumor-penetrating peptides designed to selectively target the tumor microenvironment and help therapeutic agents reach cancer cells more effectively.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is designed to activate the CendR pathway, which may increase the penetration and distribution of co-administered anticancer treatments within tumors.